Conditions: Tobacco Abstinence Syndrome
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 26
Healthy volunteers: yes

Brief summary:
This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.

Detailed description:

Arms:
arm 1: Intranasal Insulin First, Placebo Second arm 2: Placebo First, Intranasal Insulin Second

Interventions: intervention 1: Intranasal Insulin intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: